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To determine the incidence and possible causes of second primary malignancies after treatment for Hodgkin’s and Non-Hodgkin’s
lymphoma (HL and NHL). A cohort of 3764 consecutive patients diagnosed with HL or NHL between January 1970 and July 2001
was identified using the Sheffield Lymphoma Group database. A search was undertaken for all patients diagnosed with a subsequent
primary malignancy. Two matched controls were identified for each case. Odds ratios were calculated to detect and quantify any risk
factors in the cases compared to their matched controls. Mean follow-up for the cohort was 5.2 years. A total of 68 patients who
developed second cancers at least 6 months after their primary diagnosis were identified, giving a crude incidence of 1.89% overall:
3.21% among the patients treated for HL, 1.32% in those treated for NHL. Most common were bronchial, breast, colorectal and
haematological malignancies. High stage at diagnosis almost reached statistical significance in the analysis of just the NHL patients
(odds ratio¼3.48; P¼0.068) after adjustment for other factors. Treatment modality was not statistically significant in any analysis.
High stage at diagnosis of NHL may be a risk factor for developing a second primary cancer.
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‘Late effects’ of lymphoma treatment are being increasingly
documented as more patients are surviving their disease. Arguably
the most serious of these late effects is the development of a second
primary malignancy (SPM).
An association between HL and other tumours was first
documented in 1957 (Moertal and Hagendorn, 1957) when a
combined review and case series of 120 patients was published.
Since then, numerous studies have described a significantly
increased risk of second cancers in these patients. Initially, the
major risk was thought to be from second acute leukaemias
(Canellos et al, 1975; Pederson-Bjergaard and Larsen, 1982;
Valagussa et al, 1986) and associations were quickly demonstrated
with certain chemotherapy regimens such as MOPP (mustine,
Oncovin, procarbazine, prednisone) (Valagussa et al, 1986; Kaldor
et al, 1990; Tura et al, 1993). Splenectomy has also been proposed
as a risk factor (Pederson-Bjergaard and Larsen, 1982). The risk of
developing acute leukaemia appears to peak approximately 5 years
after onset of chemotherapy (Tura et al, 1993) and plateau by
approximately 10 years (Tucker et al, 1988). In contrast, the risk of
second solid cancers appears to increase with time from diagnosis
(Valagussa et al, 1986; Tucker et al, 1988; Swerdlow et al, 1992),
which means that they, in fact, are the major risk to long-term
survivors of HL. Much controversy exists as to the major risk
factors for developing second solid cancers, with many investiga-
tors finding an increased risk in all treatment groups (Tucker et al,
1988; Boivin et al, 1995; Dores et al, 2002). However, that there is
an increased risk with younger age (Swerdlow et al, 2000) and
particularly of breast cancer in women treated with radiotherapy
(RT) is now widely accepted (Janjan et al, 1988; Hancock et al,
1993; van Leeuwen et al, 1994a; Aisenberg et al, 1997).
Noticeably, less literature exists concerning second cancers in
patients treated for NHL. This may, in part, be a reflection of the
higher average age at diagnosis, the poorer survival and hence the
reduced availability of patients for long-term follow-up. However,
a significant risk of myelodysplasia and acute leukaemia has been
demonstrated in patients treated with a variety of treatment
regimens such as radiotherapy alone and high-dose chemotherapy
with autologous stem cell support (Stone, 1994; Micallef et al,
2000). An excess risk of developing certain solid cancers have
also been described, particularly bladder, kidney, lung, malignant
melanoma, HL (Travis et al, 1991) and brain tumours (Travis et al,
1993). Of these, a positive association was demonstrated between
chemotherapy and bladder cancer (Travis et al, 1993), and between
radiotherapy and lung, bladder and bone malignancies (Travis
et al, 1991). However, other studies have failed to demonstrate
any excess risk of these tumours in any treatment groups. A study
published in 1990 (Lavey et al, 1990) described an incidence of
second solid tumours similar to that expected in the general
population, with significant differences only present for salivary
gland tumours (both overall and in patients treated with
chemotherapy alone) and malignant melanomas (overall).
Where an elevated risk of solid cancers has been demonstrated,
it appears to remain significantly increased up to 20 years after
lymphoma diagnosis (Travis et al, 1993).
While it is important to determine the incidence of second
primary malignancies in survivors of both HL and NHL, it is more Received 17 January 2005; revised 6 July 2005; accepted 6 July 2005
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svital to define the risk factors for each type of malignancy, so that
either these can be modified or patients at particular risk can be
closely monitored.
PATIENTS AND METHODS
The study was a nested case–control design. In total, 3764
consecutive patients diagnosed with HL or NHL between the
January 1970 and 28 July 2001 were identified using the Sheffield
Lymphoma Group database. For all patients, information on sex,
date of birth, age at diagnosis, date of diagnosis, histology, stage
at diagnosis, presenting site, date last seen, vital status, duration
of follow-up and occurrence of second cancers was extracted from
the database. Patients who were only seen once at Weston Park
Hospital and completed all of their treatment elsewhere were
immediately excluded from the study. For the purpose of this
study, SPM is defined as any site of second malignancy either in
situ or invasive, except Kaposi’s Sarcoma in HIV positive
individuals, diagnosed at least six complete months after
lymphoma diagnosis but before death. Any cases of SPM
diagnosed in patients who received initial treatment for their
lymphoma at other centres were excluded, as were all malignancies
diagnosed within 6 months of lymphoma diagnosis and also cases
of third primary malignancies.
Two controls were identified for every case, matched as closely
as possible for their primary diagnosis (HL or NHL), sex, age at
diagnosis (72 years), duration of follow up (71 year of time from
primary diagnosis to the second cancer diagnosis), and year of
diagnosis (710 years). The group of second cancer cases and their
matched controls is the main study sample. For both the cases and
their controls, additional information was extracted from their
notes on the type and dates of treatment received, including
chemotherapy regimens, radiotherapy doses and fields, splenec-
tomy, stem cell support, and also date and diagnosis of the
subsequent primary malignancy. Information was also sought as
to the smoking status of the patients, but this was often (435%)
incomplete.
Matched conditional logistic regression (Breslow and Day, 1980)
was used to determine whether any of the variables were risk
factors for the development of an SPM. Three separate groups of
analyses were undertaken, one on all patients (either HL or NHL
disease as the first primary malignancy), one based only on NHL
patients and finally one based only on the HL patients. Since
matching was performed on age, sex, whether HD or NHL disease
as the first primary disease and the duration of follow-up, none
of these variables, or those derived from them, were included in
the analyses. However, because matching on time of diagnosis was
only performed within 10 years, in these analyses, adjustment for
the effect of time of diagnosis was performed by including it as
a covariate in the model. Thus, the variables decade of primary
diagnosis (1970–1979, 1980–1989, 1990–2001), presenting site
(nodular disease, extra-nodular disease, other (B symptoms (4),
cord compression (1), superior vena cava obstruction (1) and
alcohol pain (1)), stage (low: I and II; high: III and IV) and
treatment (radiotherapy only, chemotherapy only, radiotherapy
and chemotherapy, surgery alone/unknown treatment/no treat-
ment) were included in all three analyses. Additionally, for the
NHL patients, histology type for NHL (high grade: high-grade B
cell or high-grade T cell; other: low-grade B cell, low-grade T cell
or unknown grade) was also analysed. For the analysis of the HL
patients, histology type for HL (nodular-sclerosing; mixed cell;
other: lymphocyte depleted, lymphocyte predominant or un-
known) and having a splenectomy or not were included. The
groups for classifying histology for both HL and NHL were
necessary due to the small numbers in some of the groups. Odds
ratios (OR), 95% confidence intervals (CI) and P-values were
estimated when the variables were examined separately in
univariate models and all together in multivariate models. Odds
ratios were not presented when there were fewer than 5% of either
cases or controls in the risk factor level. All analyses were
performed in Stata version 7.0 (StataCorp, 2001).
RESULTS
In total, 3764 consecutive patients diagnosed with HL or NHL
between the January 1970 and 28 July 2001 were identified using
the Sheffield Lymphoma Group database. For the whole popula-
tion, the median duration of follow-up is 2.79 years, mean 5.19
years. There were 174 patients who were only seen once at Weston
Park Hospital and completed all of their treatment elsewhere who
were immediately excluded from the study. Figure 1 gives the
details of the remaining 3590 patients, as well as shows why 25 of
the 93 cases of second malignancies identified were excluded from
the analysis. Therefore, 68 cases of SPM met the inclusion criteria,
giving a crude incidence of 1.89% overall: 3.21% among the
patients treated for HL, 1.32% in those treated for NHL. Most
common were bronchial, breast, colorectal and haematological
malignancies. All SPMs included in the study are shown in Table 1.
Thus, matched conditional logistic regression was performed on 68
cases (35 HD, 33 NHL) and 136 controls to determine whether any
of the variables were risk factors for the development of an SPM.
All patients
When the matched conditional logistic regression was performed
on the 68 cases and 136 controls together, only decade of diagnosis
(P¼0.029) was significant in both the univariate and multivariate
models (Table 2). Patients diagnosed in 1980–1989 had half the
risk of developing an SPM than patients diagnosed in 1970–1979.
Similarly, patients diagnosed in 1990–2001 had less than a tenth
of the risk of developing an SPM than patients diagnosed in 1970–
1979 in the multivariate model. Patients diagnosed with either
stage III or IV disease had a higher risk of developing an SPM
(1.7 times) than those diagnosed with stage I or II disease, and
those patients given chemotherapy, either alone or in combination
had lower risks of developing an SPM than those patients just
having radiotherapy, although none of these were statistically
significant.
NHL patients
The analysis of the NHL patients only showed that patients with
high stage disease had 3.5 times the risk of developing an SPM
than those diagnosed with low stage disease although this was
marginally nonsignificant after adjustment for other factors in
the multivariate model (P¼0.068). Patients with NHL that was not
high grade had a lower but nonsignificant risk of developing SPM
than those with high grade NHL, and patients given chemotherapy
alone or in combination generally had a lower risk than those
given only radiotherapy, but these were not significant (Table 3).
Hodgkin’s lymphoma patients only
Table 4 presents the univariate and multivariate results for the
matched conditional logistic regression for the 35 and 70 HL cases
and controls, respectively. None of the variables reached statistical
significance for predicting whether the patient would develop an
SPM for those patients diagnosed with HL, in either the univariate
or multivariate models.
DISCUSSION
There can be no doubt that the long-term survivors of malignant
lymphoma are at increased risk of developing second cancers and
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sthat this risk results mainly from the oncogenic sequelae of
cytotoxic and/or radiation therapy (Connors, 2003; Hancock,
2003). It was surprising that we could not replicate these results,
although due to the low numbers (four cases, seven controls) in the
minimal treatment (no chemotherapy and/or radiotherapy) group
the reference category for the analyses of treatment was generally
taken as those patients having radiotherapy alone. It is quite
difficult to assess the actual risks (Henry-Amar, 2000) but is likely
that incidence of leukaemia in the first 10 years after chemother-
apy for HL is in the order of 5–10% (with a relative risk exceeding
10, compared with a matched reference population). Similar
relative risks are seen for secondary NHL 5–15 years post-
treatment. However, these conditions have a low natural incidence
so the actual number of cases is small. More seriously, for both HL
and NHL, the incidence of second solid tumours approaches 20%
after two decades (with a relative risk of only between 1.5 and 2.5,
but accounting for larger number of cases). Many of the earlier
reports were from specialist centres or clinical trial collaboratives
leading inevitably to patient selection. Our study deals with a
relatively nonselected series of consecutive patients seen at a
provincial lymphoma centre.
All lymphomas
Of the 68 SPMs identified in this study, bronchial and breast
carcinomas were most frequent, and solid cancers overall were
much more common than haematological malignancies. This
is supported by similar findings in a 1990 study of second
malignancy risk after lymphoma treatment (Moertal and
Hagendorn, 1957).
Conditional logistic regression analysis showed a nonstatistically
significant increase in the risk of developing an SPM for those
with higher stage tumours. The observed increase in the risk of
developing an SPM for those diagnosed in the decade 1970–1979
compared with those diagnosed in 1980–1989 and 1990–2001 is
almost certainly an artefact of the design with matching having
been performed on length of follow-up. The patients first
diagnosed in 1970–1979 had a longer follow-up time in which to
develop a second primary compared to the later decades, and are
3764 patients identified
174 excluded as seen only once 
at WPH  3590 potentially eligible
• 1901HL: 649 male, 442 female
• 2499 NHL: 1306 male, 1193 female
93 possible SPMs
• 14 excluded as within 6 months of diagnosis
• 5 excluded as almost all treatment for
lymphoma elsewhere
• 1 excluded as HIV positive
• 5 excluded as had a 3rd primary
68 SPMs 3497 No SPM
Study sample = 204
68 cases, 136 controls
35 HL cases; 33 NHL cases
Figure 1 Total population, exclusions and distribution of cases and controls within the study sample.
Table 1 Distribution of SPMs by lymphoma diagnosis and sex
Type of SPM
HL
male
HL
female
NHL
male
NHL
female Total
Bronchial carcinoma 4 2 5 2 13
Breast carcinoma 0 7 0 4 11
Colorectal carcinoma 1 0 4 3 8
Skin cancers 4 0 3 1 8
Leukaemia or myelodysplasia 4 2 1 0 7
Stomach carcinoma 0 1 3 0 4
Multiple myeloma 1 0 0 1 2
Prostate carcinoma 0 0 2 0 2
Brain tumours 1 0 1 0 2
Pancreatic carcinoma 1 0 1 0 2
Metastatic carcinoma, unknown primary 1 0 1 0 2
NHL 1 1 0 0 2
Bladder carcinoma 1 0 0 0 1
Cholangiocarcinoma 1 0 0 0 1
Ovarian carcinoma 0 1 0 0 1
Cardiac sarcoma 0 1 0 0 1
Anal carcinoma 0 0 0 1 1
Total 20 15 21 12 68
SPM¼second primary malignancy.
Second primary cancer in malignant lymphoma patients
A Okines et al
420
British Journal of Cancer (2005) 93(4), 418–424 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sTable 2 Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for risk factors for both HL and NHL
patients together
Factor Category
a
All patients univariate
OR (95% CI) ca 68, co 136
All patients multivariate
OR (95% CI)
Decade of diagnosis (years) 1970–1979 1.00 1.00
30, 50
1980–1989 0.50 (0.18–1.39) 0.55 (0.19–1.60)
28, 57
1990–1999 0.08
b (0.01–0.75) 0.09
c (0.01–0.94)
10, 29
Stage at diagnosis Low 1.00 1.00
43, 91
High 1.29 (0.72–2.32) 1.69 (0.72–3.95)
25, 40
Presenting site at diagnosis Nodal disease 1.00 1.00
54, 94
Extra-nodal disease 0.56 (0.25–1.27) 0.69 (0.26–1.85)
13, 36
Other — —
1, 6
Treatment given RT only 1.00 1.00
31, 54
CT only 0.87 (0.43–1.75) 0.63 (0.23–1.68)
19, 38
RT and CT 0.62 (0.28–1.39) 0.63 (0.26–1.50)
14, 37
Surgery only/no treatment/treatment u/k 0.99 (0.26–3.84) 1.05 (0.21–5.15)
4, 7
aReference category stated first.
bP¼0.029.
cP¼0.044. —, Odds ratio not presented as fewer than 5% of either cases or controls in the risk factor level.
Table 3 Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for risk factors for NHL patients only
Factor Category
a
NHL patients univariate
OR (95% CI) ca 33, co 66
NHL patients multivariate
OR (95% CI)
Decade of diagnosis (years) 1970–1979 1.00 1.00
6, 10
1980–1989 0.65 (0.13–3.16) 0.86 (0.15–4.86)
17, 32
1990–1999 0.16 (0.01–2.60) 0.22 (0.01, 4.04)
10, 24
Stage at diagnosis Low 1.00 1.00
17, 44
High 2.28 (0.97–5.36) 3.48 (0.91–13.26)
16, 17
Presenting site at diagnosis Nodal disease 1.00 1.00
20, 32
Extra-nodal disease 0.62 (0.26–1.43) 1.09 (0.34–3.53)
13, 34
Other — —
0, 0
Treatment given RT only 1.00 1.00
13, 26
CT only 1.30 (0.50–3.37) 0.56 (0.15–2.16)
12, 18
RT and CT 0.64 (0.19–2.18) 0.50 (0.11–2.29)
5, 15
Surgery only/no treatment/treatment u/k 0.92 (0.20–4.14) 0.63 (0.10–3.99)
3, 7
Histology High grade NHL 1.00 1.00
16, 30
Other NHL 0.89 (0.39–2.04) 0.70 (0.25–1.98)
17, 36
aReference category stated first. —, odds ratio not presented as fewer than 5% of either cases or controls in the risk factor level.
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slikely to have had more controls diagnosed in the later periods.
This is therefore of no particular interest.
Non-Hodgkin’s lymphoma
The incidence of SPMs in this study population is less than has
been reported in previous studies and this is especially marked in
the NHL patients, in whom a crude incidence of 1.32% is reported
here, compared to the 4.22 (Travis et al, 1991) to 8.77% (Travis
et al, 1993) reported in the literature in both small studies (Lavey
et al, 1990) and large multicentre analyses (Travis et al, 1991). This
may be a reflection of the short duration of follow-up overall for
both HL and NHL patients in this study (mean 5.19 years, median
2.79 years) compared to a median of 5.5 years (Lavey et al, 1990),
or mean of 7.4 years (Travis et al, 1993) in other studies, but the
possibility that not all cases of SPM have been recorded on the
database cannot be excluded. A simple way of increasing the mean
duration of follow-up and the overall incidence would be to limit
the cohort to patients who survived longer than 6 months. This
would give a more accurate representation of the incidence, as
patients who have died within 6 months have not actually had the
chance to develop an SPM, by this study’s definition. Additionally,
the initial determination of those developing an SPM was
performed only 6 months after the cutoff for inclusion in the
whole cohort thus reducing the mean follow-up time. Finally, 145
of the 3764 patients were lost to follow-up, and so may have in
fact developed an SPM that is not known about. These patients
comprised those who were followed-up at other hospitals, those
who went on to receive some of their treatment at local district
general hospitals and those who were discharged from clinic but
whose General Practitioners did not return the two-yearly postal
follow-up requests.
There was only a single case of leukaemia that occurred in this
patient group, which is probably significantly lower than the 11
out of 517 patients with leukaemia or myelodysplasia reported in
a 1983 study (Greene et al, 1983), or the four out of 61 patients
reported in 1996 (Travis et al, 1996), although we would need the
duration of follow-up for each of the studies to be comparable to
be certain of this. However, in the former study, the high incidence
is probably due to the intensity of the treatment received by the
patients; seven out of the nine patients had had radical radio-
therapy and one had six cycles of MOPP chemotherapy, despite
eight of the cases having had an ‘indolent NHL subtype’. Equally,
in the latter study, all patients had received low-dose total body
irradiation and chemotherapy, in contrast to our study population,
who had received treatment as diverse as node excision only and
through to intense combined modality regimens, thus making
comparison difficult.
Table 4 Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for risk factors for HL patients only
Factor Category
a
HL patients univariate
OR (95% CI) ca 35, co 70
HL patients multivariate
OR (95% CI)
Decade of diagnosis (years) 1970–1979 1.00 1.00
24, 40
1980–1989 0.45 (0.11–1.78) 0.31 (0.06, 1.56)
11, 25
1990–1999 — —
0, 5
Stage at diagnosis Low 1.00 1.00
26, 47
High 0.73 (0.31–1.73) 1.26 (0.33–4.74)
9, 23
Presenting site at diagnosis Nodal disease 1.00 1.00
34, 62
Extra-nodal disease — —
0, 2
Other — —
1, 6
Treatment given RT only 1.00 1.00
18, 28
CT only 0.53 (0.18–1.55) 0.66 (0.13–3.28)
7, 20
RT and CT 0.65 (0.22–1.95) 0.55 (0.16–1.89)
9, 22
Surgery only/no treatment/treatment u/k — —
1, 0
Histology Nodular sclerosing 1.00 1.00
13, 20
Mixed cell 0.73 (0.29–1.87) 0.69 (0.25–1.88)
14, 30
Other HL 0.63 (0.22–1.80) 0.65 (0.22–1.95)
8, 20
Splenectomy No 1.00 1.00
23, 51
Yes 1.48 (0.57–3.79) 1.51 (0.50–4.56)
12, 19
aReference category stated first. —, odds ratio not presented as fewer than 5% of either cases or controls in the risk factor level.
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sSolid tumours were far more common in our patients, with the
most frequently observed SPM being bronchial carcinoma. This
supports the findings of a 1991 multi-centre study (Travis et al,
1991), which reported 274 cases of lung cancer (more than any
other site) in 29153 patients treated for NHL. The same study
found colorectal carcinomas to be the next most frequent (186
cases), followed by breast and prostate cancers. Skin cancers had
been excluded from the analysis. In the current study, breast
carcinoma and skin cancers were common, but only two cases
of prostate cancer were recorded. Similar findings were also
published in 1993 (Travis et al, 1993), where the investigators
reported bronchial carcinoma as the most common SPM, followed
by colorectal, breast and prostate carcinomas.
From the matched conditional logistic regression analysis, the
one variable that almost reached statistical significance was stage
at diagnosis, which was only marginally nonsignificant (P¼0.068),
with patients of stages III and IV at higher risk of developing an
SPM compared to those presenting with either stage I or II disease.
This result could prove to be an independent risk factor in a larger
study, but may also have been confounded by the fact that stage I
and II disease is most likely to be treated with local radiotherapy,
whereas stage III and IV disease is more likely to have been treated
with combination chemotherapy for high-grade disease or
prolonged chlorambucil7radiotherapy for low-grade disease.
Previous studies have shown positive correlates between radio-
therapy dose and leukaemia SPM (Greene et al, 1983), radio-
therapy and leukaemia, lung, bladder and bone SPMs, and
chemotherapy and leukaemia and bladder SPM (Travis et al,
1991). As the number of patients in this study was small, separate
analyses were only carried out for the two most common SPMs,
lung and breast, for all lymphomas together, so no comparison to
other results can be made. Histological subtype did not reach
statistical significance in this study (as a risk factor for developing
an SPM). A recent study of patients with mantle cell lymphoma
(Barista et al, 2002) reported a crude incidence of 7.05% of patients
developing an SPM. Clearly, this is much higher than reported
here, but lies within the range reported in the literature, so this sort
of lymphoma may not prove to be an independent risk factor.
Hodgkin’s lymphoma
The incidence of SPMs in this group (3.21%) is slightly lower than
most previously reported (Valagussa et al, 1986; Prior and Pope,
1988; Tucker et al, 1988; Cimino et al, 1991; Swerdlow et al, 1992,
1997; Foss Abrahamsen et al, 1993), but lies within the overall
range of 2.17 (Prior and Pope, 1988) to 7.53% (Swerdlow et al,
1997).
Here, six cases of haematological malignancy were recorded
(0.55%), which is noticeably lower than the 4.35% (Pederson-
Bjergaard and Larsen, 1982) or 4.37% (Tura et al, 1993) reported
elsewhere. However, both studies selected patients treated with
a combination of MOPP chemotherapy and radiotherapy. More
recently, a study in a more heterogeneous population reported an
incidence of 2.27% (van Leeuwen et al, 1994b), which although
clearly still much higher than reported here, is more comparable to
this study. As stated previously, it is possible that the reduced
incidence reported here is a result of the relatively short duration
of follow-up and potentially incomplete records.
Solid cancers were more common than haematological SPMs,
as is the case in the literature (Canellos et al, 1975; Valagussa et al,
1986; Prior and Pope, 1988; Tucker et al, 1988; Cimino et al, 1991;
Foss Abrahamsen et al, 1993; van Leeuwen et al, 1994a; Boivin
et al, 1995; Swerdlow et al, 1997). Here, breast carcinoma was
the most common solid SPM, with seven cases (1.66%) recorded.
Again, this figure is much lower than the 2.82% (Hancock et al,
1993) or 12.61% (Aisenberg et al, 1997) previously reported.
However, in the former study, the mean duration of follow-up was
5.19 years, and in the latter, median 18 years and all patients were
aged less than 60 and had stage 1 or 2 disease and so this was also a
highly selected patient group. Bronchial carcinoma occurred in six
patients, an increased risk has also been previously reported
(Kaldor et al, 1990; van Leeuwen et al, 1995; Swerdlow et al, 2001).
In the first study of 98 cases and matched controls (Kaldor et al,
1990), the investigators found a higher risk following CT than RT.
The second study (van Leeuwen et al, 1995) related radiation dose
received by the affected area of lung to risk in their 30 cases and
controls. Most recently, in a study of 88 cases out of a cohort of
5519 (Swerdlow et al, 2001), borderline significance was found
for MOPP chemotherapy compared to other treatment regimens.
In the current study, all six of the cases received mantle RT, and
two received CT (either MOPP or L[Leukeran]OPP) for relapse.
None of the variables were statistically significant in the
conditional logistic regression analyses, although patients who
had a splenectomy had a nonsignificantly higher risk of developing
an SPM (P¼0.47) in the multivariate model. It is possible that
splenectomy would have been statistically significant if we were
able to restrict the analysis to leukaemias, as an increased risk has
been reported of 21 out of 557 splenectomised patients compared
to one out of 145 not splenectomised (P¼0.01) (Tura et al, 1993)
but the numbers in our study are too small for such an analysis.
Bronchial carcinoma SPM
When additional logistic regression analysis was undertaken on
the 13 triples for the patients having an SPM in the lung, there
were no statistically significant risk factors, although treatment
modality bordered on significance when it was grouped up as the
rest vs combination RT and CT (odds ratio: 3.70; 95% CI: 0.72,
18.97; P¼0.12). Treatment modality might well be statistically
significant if the sample size allowed valid division into HL and
NHL patients, or the treatment modalities did not need to be
grouped up. Different treatment modalities have been reported
to affect the risk of bronchial carcinoma in patients with HL;
although two studies concluded that chemotherapy was the most
important risk factor (Kaldor et al, 1990; Swerdlow et al, 2001) the
third showed radiation dose to be statistically significant (van
Leeuwen et al, 1995).
Breast carcinoma SPM
Further logistic regression analysis was carried out on the 11
triples for the cases having an SPM in the breast. Since one of the
major observations previously reported for HL cases is that there
is an increased risk with breast cancer in women treated with
radiotherapy (RT) (Janjan et al, 1988; Hancock et al, 1993; van
Leeuwen et al, 1994a; Aisenberg et al, 1997; Swerdlow et al, 1997),
we examined whether having any radiotherapy (either alone or in
combination) affected whether or not there was a breast SPM, for
all patients. We found that all of the cases (i.e. those 11 having a
breast SPM, seven of which were HL patients) were given some
form of RT, while non of the patients who were not given RT,
either alone or in combination, went on to develop a breast SPM.
Thus, while it was not possible to test this statistically, this finding
does appear to support the view that giving RT to HL patients does
increase the risk of developing breast cancer.
CONCLUSION
In this study of all patients treated in one provincial Centre, having
high stage disease at presentation, especially for NHL patients,
was only marginally nonsignificant. This may be a significant risk
factor in a larger study. Other individual factors may be important
for different SPMs and only with larger numbers of patients and
longer follow-up can these be elucidated.
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